Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

$ 4.3 Billion growth expected in Global Eczema Therapeutics Market 2021-2025 | Technavio


NEW YORK, June 23, 2021 /PRNewswire/ -- The eczema therapeutics market is expected to grow by USD 4.30 billion during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of COVID-19 pandemic on the eczema therapeutics market in optimistic, probable, and pessimistic forecast scenarios.

Request a Free Sample to understand the scope of the report

The eczema therapeutics market will witness a neutral impact during the forecast period owing to the widespread growth of the COVID-19 pandemic. As per Technavio's pandemic-focused market research, market growth is likely to increase in 2021 as compared to 2020.

Key Considerations for Market Forecast:

Major Five Eczema Therapeutics Market Participants:

AbbVie Inc.: The company offers eczema therapeutics under the brand name RINVOQ.

Alliance Pharma Plc: The company offers eczema therapeutics under the brand name Hydromol.

Bausch Health Companies Inc.: The company offers eczema therapeutics under the brand name DUOBRII Lotion.

Bayer AG: The company offers eczema therapeutics under the brand names Bepanthen and Canesten.

Eli Lilly and Co.: The company offers eczema therapeutics under the brand name OLUMIANT.

Eczema Therapeutics Market 2021-2025: Segmentation

Eczema therapeutics market is segmented as below:

The eczema therapeutics market is driven by the high prevalence of atopic dermatitis, strong pipeline landscape, and increasing product launches. In addition, other factors such as increasing healthcare expenditure and geopolitical uncertainties are expected to trigger the eczema therapeutics market toward witnessing a CAGR of over 9% during the forecast period.

Get more insights into the global trends impacting the future of the eczema therapeutics market.
Request Free Sample @ https://www.technavio.com/talk-to-us?report=IRTNTR40707

Related Reports on Healthcare Include:

Global Allergy Immunotherapies Market - Global allergy immunotherapies market is segmented by product (SCIT and SLIT) and geography (Europe, North America, Asia, and ROW).
Download Exclusive Free Sample Report

Global Allergy Rhinitis Drugs Market - Global allergy rhinitis drugs market is segmented by product (antihistamines, intranasal corticosteroids, immunotherapies, and others) and geography (North America, Europe, Asia, and ROW).
Download Exclusive Free Sample Report

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Gain instant access to 17,000+ market research reports by using
Technavio's SUBSCRIPTION platform

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Report: www.technavio.com/report/eczema-therapeutics-market-industry-analysis

SOURCE Technavio


These press releases may also interest you

at 02:00
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...

at 01:54
FIRST QUARTER (JANUARY - MARCH 2024) Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...

at 01:00
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...

at 00:01
Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients...

16 mai 2024
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash,...

16 mai 2024
Seelos Therapeutics, Inc. ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a...



News published on and distributed by: